CIK 0001770121
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Sana Biotechnology, Inc.
Sign in to watch- Ticker
- SANA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831381173
- Phone
- +1 206-701-7914
- Business address
- 188 EAST BLAINE STREET, SUITE 350, SEATTLE, WA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-08 | Flagship Ventures Fund V General Partner LLC 10% owner | Conversion | +1,487,371 | 1,487,371 | ||
| 2021-02-08 | Flagship Ventures Fund V General Partner LLC 10% owner | Conversion | +9,725,122 | 9,725,122 | ||
| 2021-02-08 | Flagship Ventures Fund V General Partner LLC 10% owner | Conversion | +11,441,326 | 11,441,326 | ||
| 2021-02-08 | Flagship Ventures Fund V General Partner LLC 10% owner | Conversion | +11,585,199 | 11,585,199 | ||
| 2021-02-08 | Flagship Ventures Fund V General Partner LLC 10% owner | Conversion · Series A-2 Convertible Preferred Stock | −1,487,371 | 0 | ||
| 2021-02-08 | Flagship Ventures Fund V General Partner LLC 10% owner | Conversion · Series A-2 Convertible Preferred Stock | −9,725,122 | 0 | ||
| 2021-02-08 | Flagship Ventures Fund V General Partner LLC 10% owner | Conversion · Series A-2 Convertible Preferred Stock | −11,441,326 | 0 | ||
| 2021-02-08 | Flagship Ventures Fund V General Partner LLC 10% owner | Conversion · Series A-2 Convertible Preferred Stock | −11,585,199 | 0 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion | +10,156,250 | 10,303,750 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion | +10,156,250 | 10,301,250 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion | +11,718,750 | 11,718,750 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion | +11,718,750 | 11,718,750 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion · Series A-1 Convertible Preferred Stock | −3,687,500 | 0 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion · Series A-1 Convertible Preferred Stock | −3,687,500 | 0 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion · Series A-2 Convertible Preferred Stock | −5,687,500 | 0 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion · Series A-2 Convertible Preferred Stock | −9,375,000 | 0 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion · Series A-2 Convertible Preferred Stock | −9,375,000 | 0 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion · Series A-2 Convertible Preferred Stock | −5,687,500 | 0 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion · Series B Convertible Preferred Stock | −781,250 | 0 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion · Series B Convertible Preferred Stock | −781,250 | 0 |
Page 14 of 16 · 315 trades